Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)
South Korea · Delayed Price · Currency is KRW 5,560.00
-50.00 (-0.89%)
Sep 19, 2025, 9:40 AM KST
Hyundai Bioscience Revenue
Hyundai Bioscience had revenue of 332.91M KRW in the quarter ending June 30, 2025, a decrease of -96.37%. This brings the company's revenue in the last twelve months to 1.87B, down -89.23% year-over-year. In the year 2024, Hyundai Bioscience had annual revenue of 15.05B with 58.73% growth.
Revenue (ttm)
1.87B
Revenue Growth
-89.23%
P/S Ratio
288.73
Revenue / Employee
27.04M
Employees
69
Market Cap
538.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15.05B | 5.57B | 58.73% |
| Dec 31, 2023 | 9.48B | 1.63B | 20.76% |
| Dec 31, 2022 | 7.85B | -1.39B | -15.04% |
| Dec 31, 2021 | 9.24B | -3.27B | -26.14% |
| Dec 31, 2020 | 12.51B | -17.57B | -58.41% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,031.69B |
| Celltrion | 3,748.95B |
| ALTEOGEN | 158.06B |
| Yuhan | 2,165.44B |
| SK Biopharmaceuticals | 620.28B |
| Peptron | 5.18B |
| PharmaResearch | 449.81B |
| ABL Bio | 94.93B |